A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: A phase II study

British Journal of Cancer

Volumn 84, Issue 9, 2001, Pages 1166-1171

  Frasci, G ^a   Nicolella, G ^a   Comella, P ^a   Carreca, I ^a   DeCataldis, G ^a   Muci, D ^a   Brunetti, C ^a   Natale, M ^a   Piantedosi, F ^a   Russo, A ^a   Palmeri, S ^a   Comella, G ^a   Panza, N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Paclitaxel; Small cell lung cancer; Topotecan; Weekly chemotherapy

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS; THROMBOCYTOPENIA; TOPOTECAN;

EID: 17844406865     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1741     Document Type: Article

References (34)

1. Phase I trial of weekly paclitaxel in advanced lung cancer
2. Phase II study of topotecan in pretreated small cell lung cancer
3. Phase I and pharmacokinetic studies of topotecan administered as 72 or 120 hr continuos infusion
4. DNA topoisomerases: Essential enzymes and lethal targets
5. A phase I study of weekly topotecan as a bolus infusion
6. Phase I study of topotecan plus carboplatin-paclitaxel in solid tumors
7. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
8. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
9. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients. A dose-finding study
10. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma
11. Paclitaxel, Carboplatin, and Topotecan in the treatment of Small Cell Lung Cancer: A phase II trial of the Minnie Pearl Cancer Research Network
12. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
13. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities
14. Phase I trial of low dose continuous topotecan infusion in patients with cancer: An active and well tolerated regimen
15. Topotecan and paclitaxel, an active couplet in untreated extensive disease small-cell lung cancer
16. Topotecan and paclitaxel in extensive stage small cell lung cancer patients without prior therapy
17. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation
18. Non parametric estimation for incomplete observations
19. A phase I study of cisplatin etoposide and paclitaxel in extensive stage small-cell lung cancer
20. A phase II trial of taxol and G-CSF in previously untreated patients with extensive stage small-cell lung cancer
21. Cancer statistics, 1998
22. Results of a phase I dose escalation trial of paclitaxel, etoposide and cisplatin followed by filgrastim in the treatment of patients with extensive stage small cell lung cancer
23. Toxicity of paclitaxel and topotecan in patients with previously untreated extensive small-cell lung cancer
24. Paclitaxel + topotecan + G-CSF for previously untreated extensive Small Cell Lung Cancer: Preliminary analysis of Cancer and Leukemia Group B (CALGB) 9430
25. Reporting results of cancer treatment
26. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies
27. Phase I trial of topotecan, paclitaxel and carboplatin in patients with advanced refractory malignancies
28. Sequences of topotecan and cisplatin phase I pharmacologic and in vitro studies to examine sequence dependence
29. Phase II study of topotecan in extensive stage Small Cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial
30. Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer
31. Optimal two-stage designs for phase II clinical trials
32. The current status of camptothecin analogoues as antitumor agents
33. Feasibility study of the combination of cisplatin, paclitaxel and topotecan in ovarian cancer patients
34. Topotecan and paclitaxel in extensive stage small-cell lung cancer as initial therapy